Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
Identifieur interne : 008F46 ( Main/Exploration ); précédent : 008F45; suivant : 008F47Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
Auteurs : Thomas Kuhnt [Allemagne] ; Axel Becker ; Steffi Pigorsch ; Tanja Pelz ; Marc Bloching ; Marcus Passmann ; Erwin Lotterer ; Gabriele H Nsgen ; Jürgen DunstSource :
- Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] [ 0179-7158 ] ; 2003.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Analyse de survie, Antinéoplasiques (administration et posologie), Antinéoplasiques (effets indésirables), Antinéoplasiques (usage thérapeutique), Antinéoplasiques d'origine végétale (administration et posologie), Antinéoplasiques d'origine végétale (usage thérapeutique), Association thérapeutique, Cisplatine (administration et posologie), Cisplatine (effets indésirables), Cisplatine (usage thérapeutique), Dosimétrie en radiothérapie, Facteurs temps, Femelle, Fractionnement de la dose d'irradiation, Humains, Muqueuse de la bouche (), Mâle, Métastase tumorale, Paclitaxel (administration et posologie), Paclitaxel (effets indésirables), Paclitaxel (usage thérapeutique), Stomatite (), Sujet âgé, Tumeurs de l'hypopharynx (mortalité), Tumeurs de l'hypopharynx (radiothérapie), Tumeurs de l'hypopharynx (traitement médicamenteux), Tumeurs de l'oropharynx (mortalité), Tumeurs de l'oropharynx (radiothérapie), Tumeurs de l'oropharynx (traitement médicamenteux), Tumeurs de la bouche (mortalité), Tumeurs de la bouche (radiothérapie), Tumeurs de la bouche (traitement médicamenteux), Tumeurs de la tête et du cou (mortalité), Tumeurs de la tête et du cou (radiothérapie), Tumeurs de la tête et du cou (traitement médicamenteux), Tumeurs du larynx (mortalité), Tumeurs du larynx (radiothérapie), Tumeurs du larynx (traitement médicamenteux), Études de cohortes, Études de suivi.
- MESH :
- administration et posologie : Antinéoplasiques, Antinéoplasiques d'origine végétale, Cisplatine, Paclitaxel.
- effets indésirables : Antinéoplasiques, Cisplatine, Paclitaxel.
- mortalité : Tumeurs de l'hypopharynx, Tumeurs de l'oropharynx, Tumeurs de la bouche, Tumeurs de la tête et du cou, Tumeurs du larynx.
- radiothérapie : Tumeurs de l'hypopharynx, Tumeurs de l'oropharynx, Tumeurs de la bouche, Tumeurs de la tête et du cou, Tumeurs du larynx.
- traitement médicamenteux : Tumeurs de l'hypopharynx, Tumeurs de l'oropharynx, Tumeurs de la bouche, Tumeurs de la tête et du cou, Tumeurs du larynx.
- usage thérapeutique : Antinéoplasiques, Antinéoplasiques d'origine végétale, Cisplatine, Paclitaxel.
- Adulte, Adulte d'âge moyen, Analyse de survie, Association thérapeutique, Dosimétrie en radiothérapie, Facteurs temps, Femelle, Fractionnement de la dose d'irradiation, Humains, Muqueuse de la bouche, Mâle, Métastase tumorale, Stomatite, Sujet âgé, Études de cohortes, Études de suivi.
English descriptors
- KwdEn :
- Adult, Aged, Antineoplastic Agents (administration & dosage), Antineoplastic Agents (adverse effects), Antineoplastic Agents (therapeutic use), Antineoplastic Agents, Phytogenic (administration & dosage), Antineoplastic Agents, Phytogenic (therapeutic use), Cisplatin (administration & dosage), Cisplatin (adverse effects), Cisplatin (therapeutic use), Cohort Studies, Combined Modality Therapy, Dose Fractionation, Female, Follow-Up Studies, Head and Neck Neoplasms (drug therapy), Head and Neck Neoplasms (mortality), Head and Neck Neoplasms (radiotherapy), Humans, Hypopharyngeal Neoplasms (drug therapy), Hypopharyngeal Neoplasms (mortality), Hypopharyngeal Neoplasms (radiotherapy), Laryngeal Neoplasms (drug therapy), Laryngeal Neoplasms (mortality), Laryngeal Neoplasms (radiotherapy), Male, Middle Aged, Mouth Mucosa (drug effects), Mouth Neoplasms (drug therapy), Mouth Neoplasms (mortality), Mouth Neoplasms (radiotherapy), Neoplasm Metastasis, Oropharyngeal Neoplasms (drug therapy), Oropharyngeal Neoplasms (mortality), Oropharyngeal Neoplasms (radiotherapy), Paclitaxel (administration & dosage), Paclitaxel (adverse effects), Paclitaxel (therapeutic use), Radiotherapy Dosage, Stomatitis (chemically induced), Survival Analysis, Time Factors.
- MESH :
- chemical , administration & dosage : Antineoplastic Agents, Antineoplastic Agents, Phytogenic, Cisplatin, Paclitaxel.
- chemical , adverse effects : Antineoplastic Agents, Cisplatin, Paclitaxel.
- chemical , therapeutic use : Antineoplastic Agents, Antineoplastic Agents, Phytogenic, Cisplatin, Paclitaxel.
- chemically induced : Stomatitis.
- drug effects : Mouth Mucosa.
- drug therapy : Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms.
- mortality : Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms.
- radiotherapy : Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms.
- Adult, Aged, Cohort Studies, Combined Modality Therapy, Dose Fractionation, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Metastasis, Radiotherapy Dosage, Survival Analysis, Time Factors.
Abstract
Simultaneous radiochemotherapy (sRCT) is the treatment of first choice in locally advanced head and neck cancers. We have tested a very aggressive combination protocol with cisplatin and escalated paclitaxel in combination with accelerated hyperfractionated radiotherapy to assess the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), overall toxicity, and response rate.
DOI: 10.1007/s00066-003-1106-0
PubMed: 14566475
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 004147
- to stream PubMed, to step Curation: 004147
- to stream PubMed, to step Checkpoint: 004147
- to stream Ncbi, to step Merge: 001726
- to stream Ncbi, to step Curation: 001726
- to stream Ncbi, to step Checkpoint: 001726
- to stream Main, to step Merge: 009255
- to stream Main, to step Curation: 008F46
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.</title>
<author><name sortKey="Kuhnt, Thomas" sort="Kuhnt, Thomas" uniqKey="Kuhnt T" first="Thomas" last="Kuhnt">Thomas Kuhnt</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Radiotherapy, Martin Luther University, Halle, Germany. thomas.kuhnt@medizin.uni-halle.de</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Radiotherapy, Martin Luther University, Halle</wicri:regionArea>
<wicri:noRegion>Halle</wicri:noRegion>
<wicri:noRegion>Halle</wicri:noRegion>
<wicri:noRegion>Halle</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Becker, Axel" sort="Becker, Axel" uniqKey="Becker A" first="Axel" last="Becker">Axel Becker</name>
</author>
<author><name sortKey="Pigorsch, Steffi" sort="Pigorsch, Steffi" uniqKey="Pigorsch S" first="Steffi" last="Pigorsch">Steffi Pigorsch</name>
</author>
<author><name sortKey="Pelz, Tanja" sort="Pelz, Tanja" uniqKey="Pelz T" first="Tanja" last="Pelz">Tanja Pelz</name>
</author>
<author><name sortKey="Bloching, Marc" sort="Bloching, Marc" uniqKey="Bloching M" first="Marc" last="Bloching">Marc Bloching</name>
</author>
<author><name sortKey="Passmann, Marcus" sort="Passmann, Marcus" uniqKey="Passmann M" first="Marcus" last="Passmann">Marcus Passmann</name>
</author>
<author><name sortKey="Lotterer, Erwin" sort="Lotterer, Erwin" uniqKey="Lotterer E" first="Erwin" last="Lotterer">Erwin Lotterer</name>
</author>
<author><name sortKey="H Nsgen, Gabriele" sort="H Nsgen, Gabriele" uniqKey="H Nsgen G" first="Gabriele" last="H Nsgen">Gabriele H Nsgen</name>
</author>
<author><name sortKey="Dunst, Jurgen" sort="Dunst, Jurgen" uniqKey="Dunst J" first="Jürgen" last="Dunst">Jürgen Dunst</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2003">2003</date>
<idno type="RBID">pubmed:14566475</idno>
<idno type="pmid">14566475</idno>
<idno type="doi">10.1007/s00066-003-1106-0</idno>
<idno type="wicri:Area/PubMed/Corpus">004147</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">004147</idno>
<idno type="wicri:Area/PubMed/Curation">004147</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">004147</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004147</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">004147</idno>
<idno type="wicri:Area/Ncbi/Merge">001726</idno>
<idno type="wicri:Area/Ncbi/Curation">001726</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001726</idno>
<idno type="wicri:doubleKey">0179-7158:2003:Kuhnt T:aggressive:simultaneous:radiochemotherapy</idno>
<idno type="wicri:Area/Main/Merge">009255</idno>
<idno type="wicri:Area/Main/Curation">008F46</idno>
<idno type="wicri:Area/Main/Exploration">008F46</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.</title>
<author><name sortKey="Kuhnt, Thomas" sort="Kuhnt, Thomas" uniqKey="Kuhnt T" first="Thomas" last="Kuhnt">Thomas Kuhnt</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Radiotherapy, Martin Luther University, Halle, Germany. thomas.kuhnt@medizin.uni-halle.de</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Radiotherapy, Martin Luther University, Halle</wicri:regionArea>
<wicri:noRegion>Halle</wicri:noRegion>
<wicri:noRegion>Halle</wicri:noRegion>
<wicri:noRegion>Halle</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Becker, Axel" sort="Becker, Axel" uniqKey="Becker A" first="Axel" last="Becker">Axel Becker</name>
</author>
<author><name sortKey="Pigorsch, Steffi" sort="Pigorsch, Steffi" uniqKey="Pigorsch S" first="Steffi" last="Pigorsch">Steffi Pigorsch</name>
</author>
<author><name sortKey="Pelz, Tanja" sort="Pelz, Tanja" uniqKey="Pelz T" first="Tanja" last="Pelz">Tanja Pelz</name>
</author>
<author><name sortKey="Bloching, Marc" sort="Bloching, Marc" uniqKey="Bloching M" first="Marc" last="Bloching">Marc Bloching</name>
</author>
<author><name sortKey="Passmann, Marcus" sort="Passmann, Marcus" uniqKey="Passmann M" first="Marcus" last="Passmann">Marcus Passmann</name>
</author>
<author><name sortKey="Lotterer, Erwin" sort="Lotterer, Erwin" uniqKey="Lotterer E" first="Erwin" last="Lotterer">Erwin Lotterer</name>
</author>
<author><name sortKey="H Nsgen, Gabriele" sort="H Nsgen, Gabriele" uniqKey="H Nsgen G" first="Gabriele" last="H Nsgen">Gabriele H Nsgen</name>
</author>
<author><name sortKey="Dunst, Jurgen" sort="Dunst, Jurgen" uniqKey="Dunst J" first="Jürgen" last="Dunst">Jürgen Dunst</name>
</author>
</analytic>
<series><title level="j">Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]</title>
<idno type="ISSN">0179-7158</idno>
<imprint><date when="2003" type="published">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Antineoplastic Agents (administration & dosage)</term>
<term>Antineoplastic Agents (adverse effects)</term>
<term>Antineoplastic Agents (therapeutic use)</term>
<term>Antineoplastic Agents, Phytogenic (administration & dosage)</term>
<term>Antineoplastic Agents, Phytogenic (therapeutic use)</term>
<term>Cisplatin (administration & dosage)</term>
<term>Cisplatin (adverse effects)</term>
<term>Cisplatin (therapeutic use)</term>
<term>Cohort Studies</term>
<term>Combined Modality Therapy</term>
<term>Dose Fractionation</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Head and Neck Neoplasms (drug therapy)</term>
<term>Head and Neck Neoplasms (mortality)</term>
<term>Head and Neck Neoplasms (radiotherapy)</term>
<term>Humans</term>
<term>Hypopharyngeal Neoplasms (drug therapy)</term>
<term>Hypopharyngeal Neoplasms (mortality)</term>
<term>Hypopharyngeal Neoplasms (radiotherapy)</term>
<term>Laryngeal Neoplasms (drug therapy)</term>
<term>Laryngeal Neoplasms (mortality)</term>
<term>Laryngeal Neoplasms (radiotherapy)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Mouth Mucosa (drug effects)</term>
<term>Mouth Neoplasms (drug therapy)</term>
<term>Mouth Neoplasms (mortality)</term>
<term>Mouth Neoplasms (radiotherapy)</term>
<term>Neoplasm Metastasis</term>
<term>Oropharyngeal Neoplasms (drug therapy)</term>
<term>Oropharyngeal Neoplasms (mortality)</term>
<term>Oropharyngeal Neoplasms (radiotherapy)</term>
<term>Paclitaxel (administration & dosage)</term>
<term>Paclitaxel (adverse effects)</term>
<term>Paclitaxel (therapeutic use)</term>
<term>Radiotherapy Dosage</term>
<term>Stomatitis (chemically induced)</term>
<term>Survival Analysis</term>
<term>Time Factors</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Analyse de survie</term>
<term>Antinéoplasiques (administration et posologie)</term>
<term>Antinéoplasiques (effets indésirables)</term>
<term>Antinéoplasiques (usage thérapeutique)</term>
<term>Antinéoplasiques d'origine végétale (administration et posologie)</term>
<term>Antinéoplasiques d'origine végétale (usage thérapeutique)</term>
<term>Association thérapeutique</term>
<term>Cisplatine (administration et posologie)</term>
<term>Cisplatine (effets indésirables)</term>
<term>Cisplatine (usage thérapeutique)</term>
<term>Dosimétrie en radiothérapie</term>
<term>Facteurs temps</term>
<term>Femelle</term>
<term>Fractionnement de la dose d'irradiation</term>
<term>Humains</term>
<term>Muqueuse de la bouche ()</term>
<term>Mâle</term>
<term>Métastase tumorale</term>
<term>Paclitaxel (administration et posologie)</term>
<term>Paclitaxel (effets indésirables)</term>
<term>Paclitaxel (usage thérapeutique)</term>
<term>Stomatite ()</term>
<term>Sujet âgé</term>
<term>Tumeurs de l'hypopharynx (mortalité)</term>
<term>Tumeurs de l'hypopharynx (radiothérapie)</term>
<term>Tumeurs de l'hypopharynx (traitement médicamenteux)</term>
<term>Tumeurs de l'oropharynx (mortalité)</term>
<term>Tumeurs de l'oropharynx (radiothérapie)</term>
<term>Tumeurs de l'oropharynx (traitement médicamenteux)</term>
<term>Tumeurs de la bouche (mortalité)</term>
<term>Tumeurs de la bouche (radiothérapie)</term>
<term>Tumeurs de la bouche (traitement médicamenteux)</term>
<term>Tumeurs de la tête et du cou (mortalité)</term>
<term>Tumeurs de la tête et du cou (radiothérapie)</term>
<term>Tumeurs de la tête et du cou (traitement médicamenteux)</term>
<term>Tumeurs du larynx (mortalité)</term>
<term>Tumeurs du larynx (radiothérapie)</term>
<term>Tumeurs du larynx (traitement médicamenteux)</term>
<term>Études de cohortes</term>
<term>Études de suivi</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antineoplastic Agents</term>
<term>Antineoplastic Agents, Phytogenic</term>
<term>Cisplatin</term>
<term>Paclitaxel</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Agents</term>
<term>Cisplatin</term>
<term>Paclitaxel</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term>
<term>Antineoplastic Agents, Phytogenic</term>
<term>Cisplatin</term>
<term>Paclitaxel</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antinéoplasiques</term>
<term>Antinéoplasiques d'origine végétale</term>
<term>Cisplatine</term>
<term>Paclitaxel</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Stomatitis</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Mouth Mucosa</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Head and Neck Neoplasms</term>
<term>Hypopharyngeal Neoplasms</term>
<term>Laryngeal Neoplasms</term>
<term>Mouth Neoplasms</term>
<term>Oropharyngeal Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antinéoplasiques</term>
<term>Cisplatine</term>
<term>Paclitaxel</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Head and Neck Neoplasms</term>
<term>Hypopharyngeal Neoplasms</term>
<term>Laryngeal Neoplasms</term>
<term>Mouth Neoplasms</term>
<term>Oropharyngeal Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Tumeurs de l'hypopharynx</term>
<term>Tumeurs de l'oropharynx</term>
<term>Tumeurs de la bouche</term>
<term>Tumeurs de la tête et du cou</term>
<term>Tumeurs du larynx</term>
</keywords>
<keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Head and Neck Neoplasms</term>
<term>Hypopharyngeal Neoplasms</term>
<term>Laryngeal Neoplasms</term>
<term>Mouth Neoplasms</term>
<term>Oropharyngeal Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="radiothérapie" xml:lang="fr"><term>Tumeurs de l'hypopharynx</term>
<term>Tumeurs de l'oropharynx</term>
<term>Tumeurs de la bouche</term>
<term>Tumeurs de la tête et du cou</term>
<term>Tumeurs du larynx</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs de l'hypopharynx</term>
<term>Tumeurs de l'oropharynx</term>
<term>Tumeurs de la bouche</term>
<term>Tumeurs de la tête et du cou</term>
<term>Tumeurs du larynx</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques</term>
<term>Antinéoplasiques d'origine végétale</term>
<term>Cisplatine</term>
<term>Paclitaxel</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Cohort Studies</term>
<term>Combined Modality Therapy</term>
<term>Dose Fractionation</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neoplasm Metastasis</term>
<term>Radiotherapy Dosage</term>
<term>Survival Analysis</term>
<term>Time Factors</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Analyse de survie</term>
<term>Association thérapeutique</term>
<term>Dosimétrie en radiothérapie</term>
<term>Facteurs temps</term>
<term>Femelle</term>
<term>Fractionnement de la dose d'irradiation</term>
<term>Humains</term>
<term>Muqueuse de la bouche</term>
<term>Mâle</term>
<term>Métastase tumorale</term>
<term>Stomatite</term>
<term>Sujet âgé</term>
<term>Études de cohortes</term>
<term>Études de suivi</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Simultaneous radiochemotherapy (sRCT) is the treatment of first choice in locally advanced head and neck cancers. We have tested a very aggressive combination protocol with cisplatin and escalated paclitaxel in combination with accelerated hyperfractionated radiotherapy to assess the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), overall toxicity, and response rate.</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
</country>
</list>
<tree><noCountry><name sortKey="Becker, Axel" sort="Becker, Axel" uniqKey="Becker A" first="Axel" last="Becker">Axel Becker</name>
<name sortKey="Bloching, Marc" sort="Bloching, Marc" uniqKey="Bloching M" first="Marc" last="Bloching">Marc Bloching</name>
<name sortKey="Dunst, Jurgen" sort="Dunst, Jurgen" uniqKey="Dunst J" first="Jürgen" last="Dunst">Jürgen Dunst</name>
<name sortKey="H Nsgen, Gabriele" sort="H Nsgen, Gabriele" uniqKey="H Nsgen G" first="Gabriele" last="H Nsgen">Gabriele H Nsgen</name>
<name sortKey="Lotterer, Erwin" sort="Lotterer, Erwin" uniqKey="Lotterer E" first="Erwin" last="Lotterer">Erwin Lotterer</name>
<name sortKey="Passmann, Marcus" sort="Passmann, Marcus" uniqKey="Passmann M" first="Marcus" last="Passmann">Marcus Passmann</name>
<name sortKey="Pelz, Tanja" sort="Pelz, Tanja" uniqKey="Pelz T" first="Tanja" last="Pelz">Tanja Pelz</name>
<name sortKey="Pigorsch, Steffi" sort="Pigorsch, Steffi" uniqKey="Pigorsch S" first="Steffi" last="Pigorsch">Steffi Pigorsch</name>
</noCountry>
<country name="Allemagne"><noRegion><name sortKey="Kuhnt, Thomas" sort="Kuhnt, Thomas" uniqKey="Kuhnt T" first="Thomas" last="Kuhnt">Thomas Kuhnt</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 008F46 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 008F46 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:14566475 |texte= Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:14566475" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
![]() | This area was generated with Dilib version V0.6.31. | ![]() |